Key facts
- This page summarizes Eric Morgen's Form 3 filing for BioAge Labs, Inc. (BIOA).
- 0 reported transactions and 11 derivative rows are listed below.
- Accepted by SEC: 25 Sep 2024, 16:47.
Eric Morgen - 25 Sep 2024 Form 3 Insider Report for BioAge Labs, Inc. (BIOA)
- Reporting relationship
- Chief Operating Officer, Director
- Issuer ticker
- BIOA
- Reported as of
- 25 Sep 2024
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 25 Sep 2024, 16:47:11 UTC
- Prior SEC filing
- 27 Sep 2024
- Next SEC filing
- 25 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Dov A. Goldstein as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eric Morgen filed Form 3 for BioAge Labs, Inc. (BIOA) on 25 Sep 2024.
Change
- Previous filing in this sequence was filed on 27 Sep 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BIOA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 67,225
- Date
- 25 Sep 2024
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BIOA
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 25 Sep 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 79,399
- Exercise price
- $3.08
- Footnotes
- F1
BIOA
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 25 Sep 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 92,815
- Exercise price
- $10.27
- Footnotes
- F2
BIOA
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 25 Sep 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 42,867
- Exercise price
- $6.57
- Footnotes
- F3
BIOA
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 25 Sep 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 42,867
- Exercise price
- $10.85
- Footnotes
- F4
BIOA
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 25 Sep 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 257,973
- Exercise price
- $8.39
- Footnotes
- F5
BIOA
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 25 Sep 2024
- Ownership
- By Spouse
- Underlying class
- Common Stock
- Underlying amount
- 1,233
- Exercise price
- $3.89
- Footnotes
- F6, F7
BIOA
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 25 Sep 2024
- Ownership
- By Spouse
- Underlying class
- Common Stock
- Underlying amount
- 493
- Exercise price
- $4.11
- Footnotes
- F7, F8
BIOA
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 25 Sep 2024
- Ownership
- By Spouse
- Underlying class
- Common Stock
- Underlying amount
- 6,274
- Exercise price
- $10.27
- Footnotes
- F7, F9
BIOA
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 25 Sep 2024
- Ownership
- By Spouse
- Underlying class
- Common Stock
- Underlying amount
- 2,464
- Exercise price
- $6.57
- Footnotes
- F7, F10
BIOA
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 25 Sep 2024
- Ownership
- By Spouse
- Underlying class
- Common Stock
- Underlying amount
- 2,464
- Exercise price
- $10.85
- Footnotes
- F7, F11
BIOA
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 25 Sep 2024
- Ownership
- By Spouse
- Underlying class
- Common Stock
- Underlying amount
- 13,598
- Exercise price
- $8.39
- Footnotes
- F7, F12
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 12 footnotes
Footnote F1
The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on February 21, 2022.
Footnote F2
The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on January 16, 2021, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
Footnote F3
The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on April 1, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
Footnote F4
The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on April 1, 2023, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
Footnote F5
The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on May 17, 2024, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Additionally, the entire award is exercisable at any time pursuant to an early exercise feature of the option award.
Footnote F6
The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on September 25, 2023.
Footnote F7
Represents an employee stock option directly held by the reporting person's spouse.
Footnote F8
The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on February 24, 2024.
Footnote F9
The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on March 15, 2021, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
Footnote F10
The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on April 1, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
Footnote F11
The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on April 1, 2023, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
Footnote F12
The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on May 17, 2024, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.